SynergiQc-International: New funding opportunity for public-private biopharmaceutical research


Partagez l'article

The SynergiQc-International program is geared to support public/private research with partners outside the province of Quebec !


Montreal, July 16th, 2019 – CQDM has launched the SynergiQc-International funding program that may cover up to 50% of R&D expenses incurred in Quebec as part of a public/private partnership in the biopharmaceutical field, up to a maximum of $500,000.

Eligible research and innovation initiatives must involve at least:

  • One public research institution in Quebec where research activities eligible for funding will take place;
  • One Quebec company (priority given to SMEs) that will fund, in cash, a minimum of 20% of the Quebec portion of the project;
  • One public or private partner from another Canadian province or abroad that will actively participate in the project and provide a cash or in-kind contribution totalling at least 30% of all project expenses.

This program is designed to be flexible and straightforward in order to benefit as many local researchers and companies as possible!

Refer to the SynergiQc-international website for funding details. The deadline for sending proposals to CQDM is October 7th, 2019. Interested researchers and entrepreneurs are invited to contact Marc Thibault or Véronique Dugas for more information.


About CQDM
CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the drug discovery and development. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. Over the last 10 years, CQDM has benefited from the contribution of 13 industrial members: that includes Merck, Pfizer, AstraZeneca as founding members as well as Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Roche, Sanofi Canada, Servier, Takeda and now Amgen. CQDM also received contributions from Quebec’s Ministry of Economy and Innovation (MEI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). Since 2008, CQDM has supported the development of 64 outstanding innovative technologies totaling $68 M in funding. These R&D projects carried out by 1,200 scientists from 69 different research institutions (38 public and 31 private) across Canada, have generated numerous economic benefits for all the stakeholders of the life science ecosystem.  For more information: https://cqdm.orgen

For additional information, please contact:

Véronique Dugas, Ph.D., MBA
Director, Fonds d\’accélération des collaborations en santé

Marc Thibault, Ph.D.
Director of Business Development

Scroll to Top